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a b s t r a c t
Dehydrogenases that use ubiquinone as an electron acceptor, including complex I of the respiratory
chain, complex II, and glycerol-3-phosphate dehydrogenase, are known to be direct generators of
superoxide and/or H2O2. Dihydroorotate dehydrogenase oxidizes dihydroorotate to orotate and reduces
ubiquinone to ubiquinol during pyrimidine metabolism, but it is unclear whether it produces superoxide
and/or H2O2 directly or does so only indirectly from other sites in the electron transport chain. Using
mitochondria isolated from rat skeletal muscle we establish that dihydroorotate oxidation leads to
superoxide/H2O2 production at a fairly high rate of about 300 pmol H2O2 min1 mg protein1 when
oxidation of ubiquinol is prevented and complex II is uninhibited. This H2O2 production is abolished by
brequinar or leﬂunomide, known inhibitors of dihydroorotate dehydrogenase. Eighty percent of this rate
is indirect, originating from site IIF of complex II, because it can be prevented by malonate or atpenin A5,
inhibitors of complex II. In the presence of inhibitors of all known sites of superoxide/H2O2 production
(rotenone to inhibit sites in complex I (site IQ and, indirectly, site IF), myxothiazol to inhibit site IIIQo in
complex III, and malonate plus atpenin A5 to inhibit site IIF in complex II), dihydroorotate dehydrogenase
generates superoxide/H2O2, at a small but signiﬁcant rate (23 pmol H2O2 min1 mg protein1), from
the ubiquinone-binding site. We conclude that dihydroorotate dehydrogenase can generate superoxide
and/or H2O2 directly at low rates and is also capable of indirect production at higher rates from other
sites through its ability to reduce the ubiquinone pool.
& 2014 Elsevier Inc. All rights reserved.
The biosynthesis of pyrimidine is an essential part of cell
proliferation. Most mammalian cells have two pathways for
pyrimidine synthesis, de novo and salvage. The de novo pathway
involves six enzymatic steps, ﬁve in the cytosol and one in the
mitochondria (Fig. 1), where dihydroorotate is converted to orotate
in a reversible reaction catalyzed by dihydroorotate dehydrogen-
ase [1]. There are also salvage pathways in which uracil is
regenerated from various compounds in nucleotide metabolism.
Proliferating cells have a great requirement for de novo pyrimidine
biosynthesis; therefore dihydroorotate dehydrogenase is a phar-
maceutical target for small-molecule inhibitors to treat cancer and
autoimmune diseases and for immunosuppression. The two best-
known inhibitors of dihydroorotate dehydrogenase are brequinar
and leﬂunomide. Both have been extensively tested, but only
leﬂunomide is currently available as a pharmaceutical and is
licensed for the treatment of psoriatic and rheumatoid arthritis [1].
The dihydroorotate dehydrogenases can be divided into two
broad families based on alignment of sequences from different
organisms, subcellular location, and preference for electron accep-
tor [2]. Eukaryotes and most gram-negative bacteria, including
Escherichia coli, have dihydroorotate dehydrogenases belonging to
family 2. In eukaryotes, dihydroorotate dehydrogenase is located
in the mitochondrial inner membrane with the dihydroorotate
binding site facing the intermembrane space and a hydrophobic tail
inserted in the membrane [3]. Family 2 dihydroorotate dehydro-
genases contain two redox-active sites: a ﬂavin mononucleotide
prosthetic group, which accepts two electrons from dihydrooro-
tate, and a ubiquinone in the quinone binding site, which subse-
quently accepts the electrons and joins the pool of ubiquinone in
the membrane (the Q-pool)1 [4]. Quinone reduction involves two
single-electron transfers and it is likely that a semireduced ﬂavin
intermediate is formed during the catalytic cycle [5]. The midpoint
potential of the ﬂavin in puriﬁed E. coli dihydroorotate dehydro-
genase is sufﬁciently negative (310 mV) to make this enzyme a
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good electron donor to oxygen to generate superoxide and/or
H2O2 [5] although the reactivity with quinone substrates is 14- to
58-fold higher [6].
In early studies, Forman and Kennedy concluded that super-
oxide was produced by isolated mitochondria during dihydroor-
otate oxidation [7,8]. However, the same group later concluded
that the source of superoxide lay outside dihydroorotate dehy-
drogenase and was likely to be complex III [9]. In contrast, a recent
study [10] investigating the reactive oxygen species-induced
apoptotic effect of N-(4-hydroxyphenyl)retinamide concluded that
the reactive oxygen species most likely originated from dihydroor-
otate dehydrogenase itself, because manipulating dihydroorotate
dehydrogenase protein content and activity also affected cellular
levels of reactive oxygen species. However, these results could be
explained by changes in superoxide/H2O2 production from other
Q-pool-linked sites when the reduction state of the Q-pool was
altered by manipulating electron input through dihydroorotate
dehydrogenase. Thus, they do not show that dihydroorotate
dehydrogenase itself generates superoxide/H2O2 in situ.
The mitochondrial electron transport chain and matrix contain
several protein complexes that have ﬂavins and ubiquinone binding
sites with the capacity to produce superoxide/H2O2. Fig. 1 shows the
sites at the potential of the Q-pool. Our group is characterizing
mitochondrial sites of superoxide/H2O2 production and developing
methods for measuring the contribution of each site under different
conditions [11–16]. In a recent study we found that mitochondria
isolated from rat skeletal muscle produced superoxide/H2O2 when
oxidizing dihydroorotate under conditions that should prevent
contributions from other known sites, implicating dihydroorotate
dehydrogenase as a direct generator of superoxide/H2O2 in isolated
mitochondria [11]. The objective of the present study was to more
fully characterize the sources of superoxide/H2O2 production during
dihydroorotate oxidation. We found that dihydroorotate dehydro-
genase itself can generate superoxide/H2O2 at a small rate of about
20–30 pmol H2O2 min1 mg protein1 in rat skeletal muscle
mitochondria and can drive superoxide/H2O2 production at
10-fold higher rates from other sites.
Materials and methods
Animals, mitochondrial preparation, and reagents
Female Wistar rats (Harlan Laboratories), age 5–8 weeks, were
fed chow ad libitum and given free access to water. Skeletal muscle
mitochondria were isolated in ice-cold Chappell–Perry medium
(100 mM KCl, 50 mM Tris, 2 mM EGTA, pH 7.4 at 4 1C) by standard
procedures [17]. Protein concentration was determined using the
biuret method. The animal protocol was approved by the Buck
Institute Animal Care and Use Committee, in accordance with NIH
guidelines for the care and use of laboratory animals. All reagents
were from Sigma (St. Louis, MO, USA) except for Amplex UltraRed
(Invitrogen, Carlsbad, CA, USA) and atpenin A5 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA).
Mitochondrial respiration
Oxygen consumption rate was measured using an XF24 extra-
cellular ﬂux analyzer (Seahorse Bioscience) [18]. Ten micrograms of
mitochondria (2 μg when using succinate plus rotenone) was added
to each well in a volume of 20 ml and centrifuged for 15 min
at 2000 g. Total well volume was brought to 500 μl with KHEPMB
medium, comprising 120 mM KCl, 5 mM Hepes, 5 mM K2HPO4,
1 mM EGTA, 2 mM MgCl2, and 0.3% (w/v) bovine serum albu-
min (pH 7.0 at 37 1C). The uncoupled oxygen consumption rate
was measured in the presence of 1 mM ADP, 1 μg ml1 oligo-
mycin, 1 μM carbonylcyanide 4-(triﬂuoromethoxy)phenylhydrazone
(FCCP), and 20 μM leﬂunomide, 10 μM brequinar, or vehicle
(dimethyl sulfoxide; DMSO). After the basal respiration rate was
determined, substrates were added. Substrate combinations were
Fig. 1. The QH2/Q isopotential group and its component superoxide/H2O2-producing enzymes, including dihydroorotate dehydrogenase. For comparison, see also the sites of
superoxide/H2O2 production in the NADH/NADþ isopotential group [32] and the overall scheme of electron ﬂow and superoxide/H2O2 production in the various
mitochondrial isopotential groups [33]. The background plane represents the QH2/Q isopotential group of redox centers operating at a redox potential (Eh) of approximately
þ20 mV. Their redox state is reported by the redox state of cytochrome b566 [15]. Normal electron ﬂow from complex I through sites IF and IQ to ubiquinone (QH2/Q) and
then through site IIIQo of complex III, cytochrome c (cyt c), and complex IV to oxygen at Eh þ600 mV is indicated by large pale arrows. Ovals represent other enzymes that
reduce Q; circles denote their ﬂavin (F)- and ubiquinone (Q)-linked redox sites—complex II (sites IIF and IIQ) [12], mitochondrial glycerol-3-phosphate dehydrogenase
(mGPDH) (sites GF and GQ) [11], the electron-transferring ﬂavoprotein (ETF) and ETF:ubiquinone oxidoreductase (ETF:QOR) system of acyl CoA oxidation (sites EF and EQ)
[13], and dihydroorotate dehydrogenase (DHODH) (sites DF and DQ). Sites in the QH2/Q isopotential group that generate superoxide/H2O2 are indicated in a darker shade.
Sites of action of relevant inhibitors are shown by blunted arrows. The de novo pyrimidine biosynthesis pathway from glutamine and bicarbonate to UMP is shown
associated with dihydroorotate dehydrogenase. With dihydroorotate as substrate, electron ﬂow was controlled using inhibitors: in Fig. 2 rotenone blocked site IQ (and access
from QH2 to site IF), antimycin A blocked site IIIQi, and atpenin A5 and malonate blocked complex II, leaving site IIIQo open so electrons from dihydroorotate reduced
cytochrome b566 unless brequinar or leﬂunomide was added to inhibit site DQ. In Figs. 3 and 4 sites IQ and IIIQo were blocked by rotenone, antimycin A, and myxothiazol, so
electrons from dihydroorotate passed through sites DF and DQ, producing superoxide and/or H2O2, into the QH2/Q pool, and then back into complex II through site IIQ to site
IIF, producing superoxide/H2O2. Addition of malonate blocked site IIF directly, and addition of atpenin A5 blocked access to site IIF through site IIQ (Fig. 3), whereas addition of
brequinar or leﬂunomide blocked site DQ and reduction of Q, indirectly preventing superoxide/H2O2 production by site IIF (Fig. 4). In Fig. 6 sites IQ, IIIQo, and IIF were inhibited
by rotenone, antimycin A, myxothiazol, atpenin A5, and malonate, and sites EF and GQ were inactive because of lack of acyl-CoA and glycerol 3-phosphate, leaving only site
DQ active. Its production of superoxide/H2O2 was inhibited by brequinar and partially by leﬂunomide.
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5 mM succinate plus 4 μM rotenone, 5 mM glycerol phosphate
(disodium rac-α/β-glycerol phosphate; 25% active optical isomer
sn-glycerol 3-phosphate) plus 4 μM rotenone, 5 mM glutamate plus
5 mMmalate, and 15 μM palmitoyl-L-carnitine plus 2 mM carnitine.
Finally, 1 μM antimycin A and 1 μM myxothiazol were added to
establish the nonmitochondrial oxygen consumption rate.
Mitochondrial H2O2 production
Rates of superoxide and/or H2O2 production were determined as
rates of H2O2 production after conversion of superoxide to H2O2 by
endogenous mitochondrial superoxide dismutase (SOD). H2O2 was
detected using horseradish peroxidase to catalyze the oxidation of
Amplex UltraRed by H2O2 to its ﬂuorescent resoruﬁn product [15,16].
Exogenous SOD was added to convert any superoxide released from
the mitochondria. Mitochondria (0.3 mg protein ml1) were sus-
pended in KHEPMB medium at 37 1C, together with 5 Uml1
horseradish peroxidase, 25 Uml1 SOD, and 50 μM Amplex Ultra-
Red. The ﬂuorescence signal was recorded using a Varian Cary Eclipse
spectroﬂuorimeter (λexcitation 560 nm, λemission 590 nm) with con-
stant stirring. The rate of change of ﬂuorescence was converted to
H2O2 production rate using known amounts of H2O2 as standards
under the exact conditions of the assay.
Cytochrome b566 reduction state
Experiments were performed using 1.5 mg mitochondrial
protein ml1 in KHEPMB medium. The reduction state of endo-
genous cytochrome b566 was measured with constant stirring at
37 1C in an Olis DW 2 dual-wavelength spectrophotometer at
A566–A575 nm [16]. The signal at this wavelength pair reports
75% cytochrome b566 and 25% cytochrome b562 [16,19]. Cyto-
chrome b566 was assumed to be 0% reduced after 5 min stabiliza-
tion without added substrate in samples containing DMSO, 20 μM
leﬂunomide, or 10 μM brequinar. Antimycin A was added to report
reduction caused by endogenous substrates and then dihydroor-
otate was added. The protocol was ﬁnalized by addition of 5 mM
succinate plus 10 mM glycerol phosphate. Under this condition
cytochrome b566 was assumed to be 100% reduced. All values were
related to the 0 and 100% values.
Statistics
Data are presented as the mean7SEM. Signiﬁcance of differ-
ences between conditions was tested using a one-way ANOVA with
repeated measures. If a difference was detected, Tukey's multiple
comparisons test was used post hoc. Student's one-sample t test
was used to test if measures were different from 0. p values of
o0.05 were regarded as statistically signiﬁcant.
Results and discussion
Dihydroorotate dehydrogenase activity in rat skeletal muscle
mitochondria
Dihydroorotate dehydrogenase is widely distributed in mam-
malian tissues, particularly in cells with a high proliferation rate
[20]. We chose to measure its contribution to H2O2 production in
rat skeletal muscle mitochondria, because we have extensive data
on the activities of other sites in this system [21], allowing more
valid comparisons of superoxide/H2O2 production rates. However,
skeletal muscle has a relatively low proliferation rate and low
levels of dihydroorotate dehydrogenase [20]. To check the activity
of dihydroorotate dehydrogenase in rat skeletal muscle mitochon-
dria we determined the dihydroorotate-dependent respiration
rate. However, this rate was too low (o2 nmol O2 min1 mg
protein1) to be distinguishable from background. As a more
sensitive alternative assay, we determined the ability of dihy-
droorotate to reduce the endogenous Q-pool in the mitochondrial
inner membrane in the presence of antimycin A to inhibit
reoxidation of the Q-pool by complex III. Q-pool reduction was
measured by its surrogate, the reduction level of cytochrome b566
[16]. The reduction level of cytochrome b566 was determined in the
presence of 4 μM rotenone (to inhibit complex I) and 5 mM
malonate and 1 μM atpenin A5 (to inhibit complex II) to minimize
any contribution of endogenous substrates to Q-pool reduction
(Fig. 2). Addition of dihydroorotate increased cytochrome b566
reduction state to 35%, which was signiﬁcantly higher than the
prior reduction level in the presence of antimycin A. Reduction of
cytochrome b566 was abolished by addition of brequinar or
leﬂunomide (Fig. 2), known inhibitors of dihydroorotate dehydro-
genase [22–26]. These results demonstrate that dihydroorotate
dehydrogenase is active in rat skeletal muscle mitochondria and is
capable of reducing the Q-pool.
H2O2 production by rat skeletal muscle mitochondria in the presence
of dihydroorotate
H2O2 production driven by dihydroorotate oxidation was
determined in the presence of 4 μM rotenone (to inhibit super-
oxide production by site IQ) and 2 mM antimycin A and 2 μM
myxothiazol (to inhibit Q-pool oxidation by complex III and
superoxide production by site IIIQo of complex III). The addition
of dihydroorotate did not increase NAD(P)H reduction level;
therefore we can rule out any contribution of superoxide produc-
tion from site IF (data not shown). Fig. 3a shows the dependence of
the observed rate of H2O2 production on the concentration of
dihydroorotate. Half-maximal rate was reached at approximately
10 μM dihydroorotate and leveled off between 50 μM and 3.5 mM
dihydroorotate. Dihydroorotate at 3.5 mM was chosen as the
concentration that would induce maximal dihydroorotate dehy-
drogenase activity in subsequent assays.
When the Q-pool is reduced, complex II can accept electrons
from QH2 and produce superoxide/H2O2 at site IIF [11,12]; see
Fig. 1. Fig. 3b shows that addition of 3.5 mM dihydroorotate in a
separate series of experiments (also in the presence of rotenone,
antimycin A, and myxothiazol) led to a substantial rate of H2O2
production, 315735 pmol min1 mg protein1. To test the con-
tribution of site IIF with dihydroorotate as substrate, we inhibited
Fig. 2. Effect of dihydroorotate on the reduction level of cytochrome b566 in rat
skeletal muscle mitochondria. Cytochrome b566 reduction was measured in the
presence of 5 mM malonate, 1 μM atpenin A5, and 4 μM rotenone and 10 μM
brequinar or 20 μM leﬂunomide (where indicated). 2 μM antimycin A was added to
show any reduction caused by endogenous substrates, followed by 3.5 mM
dihydroorotate. Negative values indicate apparent oxidation of cytochrome b566
below the baseline. Data are means 7SEM (n ¼ 3). np o 0.05 compared to the
level with antimycin A under the same condition.
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site IIF by addition of 5 mM malonate (an inhibitor of complex II
that competes with substrate at the substrate-binding ﬂavin site,
site IIF) and 1 μM atpenin A5 (a site IIQ inhibitor that prevents ﬂow
of electrons from the Q-pool to site IIF). Malonate and atpenin A5
each inhibited approximately 80% of the H2O2 production (Fig. 3b).
This shows that most of the observed H2O2 production with
dihydroorotate as substrate under these conditions originated
not from dihydroorotate dehydrogenase but from site IIF.
Inhibitory effects of brequinar and leﬂunomide
Brequinar and leﬂunomide are commonly used inhibitors of
dihydroorotate dehydrogenase, and several inhibitory sites have
been proposed for each inhibitor [22–26]. This issue is not fully
resolved, but recent literature [26] suggests that brequinar com-
petitively inhibits the ubiquinone-binding site of dihydroorotate
dehydrogenase. Leﬂunomide is a prodrug and its active metabolite
A771726 also inhibits the ubiquinone-binding site, but noncom-
petitively and in the binding domain of the hydrophobic tail of
ubiquinone. Neither compound inhibits at the dihydroorotate-
binding ﬂavin site [26].
The characteristics of the inhibitory effects of brequinar and
leﬂunomide were investigated by titrating their effects on H2O2
production driven by 3.5 mM dihydroorotate under the conditions
described above. Both brequinar and leﬂunomide caused a steep
decrease in H2O2 production rate with increasing inhibitor con-
centrations (Fig. 4a and b). For further experiments we chose to
use 10 mM brequinar or 20 mM leﬂunomide for full inhibition of
dihydroorotate dehydrogenase.
Both brequinar and leﬂunomide can inhibit succinate and
NADH oxidation in submitochondrial particles from kidney, liver,
and heart [27]. We tested the off-target effects of brequinar and
leﬂunomide during uncoupled respiration with various substrates
(Fig. 5). Neither 10 μM brequinar nor 20 μM leﬂunomide signiﬁ-
cantly affected uncoupled respiration with glutamate plus malate
(Fig. 5b), glycerol 3-phosphate plus rotenone (Fig. 5c), or palmi-
toyl-L-carnitine plus carnitine (Fig. 5d) as substrate. However, both
inhibitors caused a signiﬁcant 25% decrease in respiration with
succinate plus rotenone (Fig. 5a). This is in accordance with a
previous study [27], in which 50 μM leﬂunomide or 50 μM
brequinar inhibited succinate oxidation to 91 and 73% of control,
respectively, in heart mitochondria. Both results show that these
inhibitors are not speciﬁc for dihydroorotate dehydrogenase but
can also inhibit complex II. This effect may have inﬂuenced
inhibition of superoxide/H2O2 production from site IIF by brequi-
nar and leﬂunomide (Fig. 4), but this should not affect our general
conclusions.
Superoxide/H2O2 production by dihydroorotate dehydrogenase
Fig. 6 shows superoxide/H2O2 production driven by dihydroor-
otate under conditions under which all other known Q-pool-linked
sites of superoxide/H2O2 production were inhibited, particularly site
IIF, the major site operating under the conditions of Figs. 3 and 4.
Fig. 3. Superoxide/H2O2 production driven by dihydroorotate in rat skeletal muscle mitochondria. Mitochondria were incubated in the presence of 4 μM rotenone, 2 μM
antimycin A, and 2 μM myxothiazol; H2O2 production was initiated by addition of 3.5 mM dihydroorotate (DHO). (a) Dependence of measured H2O2 production rate on
dihydroorotate concentration. (b) Effect of 5 mM malonate or 1 mM atpenin A5. Data are means7SEM (n ¼ 4). np o 0.05 compared to DHO.
Fig. 4. Inhibition of dihydroorotate-induced H2O2 production by brequinar and leﬂunomide. The effects of (a) brequinar and (b) leﬂunomide on measured H2O2 production
induced by addition of 3.5 mM dihydroorotate are shown. Rat skeletal muscle mitochondria were incubated in the presence of 4 μM rotenone, 2 μM antimycin A, and 2 μM
myxothiazol. Data are means 7 SEM (n ¼ 3).
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Site IQ was inhibited by addition of 4 μM rotenone, site IIF was
inhibited by addition of 5 mM malonate and 1 μM atpenin A5, and
site IIIQo was inhibited by addition of 2 μM myxothiazol and 2 μM
antimycin A; see Fig. 1. Addition of dihydroorotate caused a
signiﬁcant (p ¼ 0.002) rate of H2O2 production of about 30 pmol -
min1 mg protein1, putatively from the only site open under
these conditions, dihydroorotate dehydrogenase itself (Fig. 6). The
rate of H2O2 production induced by addition of dihydroorotate
under these conditions was much diminished in the presence of
10 μM brequinar (p ¼ 0.006) and was not signiﬁcantly different
from zero H2O2 production (p ¼ 0.06; Fig. 6). In the presence of
20 μM leﬂunomide, dihydroorotate caused a signiﬁcant (p ¼
0.002) increase in H2O2 production but the H2O2 production rate
was only 65% of the rate without leﬂunomide (p ¼ 0.08). Based on
these results we conclude that dihydroorotate dehydrogenase is
indeed able to generate superoxide and/or H2O2 at low but
measurable rates. The brequinar-sensitive rate attributed to dihy-
droorotate dehydrogenase was 2372 pmol H2O2 min1 mg
protein1.
Mammalian dihydroorotate dehydrogenase contains two
potential sites for production of superoxide and/or H2O2: the
ﬂavin at the dihydroorotate oxidation site and the ubiquinone
reduction site. As shown with other enzymes and complexes, the
speciﬁc sites within an enzyme that generate superoxide/H2O2 can
be determined if speciﬁc inhibitors of each site are available [11–16].
In the present study brequinar, which speciﬁcally inhibits the
ubiquinone reduction site but leaves the ﬂavin site open [26], fully
inhibited production of superoxide/H2O2 driven by oxidation of
dihydroorotate (Fig. 6). Therefore, we can safely conclude that the
ﬂavin site of dihydroorotate dehydrogenase was not the source of
the H2O2 production observed in Fig. 6, implying that it was
exclusively from the Q-binding site. The results with leﬂunomide
are more complex, because its mechanism is less clear [26], and it
did not fully inhibit the H2O2 production observed in Fig. 6.
Leﬂunomide fully prevented reduction of cytochrome b566 by
dihydroorotate (Fig. 2), so the residual rate in Fig. 6 was not from
other sites taking electrons from the Q-pool, but was from a site
upstream of the site of inhibition by leﬂunomide, i.e., either the
Q-binding site or the ﬂavin of dihydroorotate dehydrogenase.
Because the result with brequinar excludes the ﬂavin site, we
conclude that leﬂunomide prevents reduction of the Q-pool at the
Q-binding site of dihydroorotate dehydrogenase, but only partially
inhibits the reduction of oxygen to generate superoxide and/or
H2O2 at this site.
Conclusions
There are at least 10 sites in the mitochondrial electron
transport chain and matrix that are able to produce superoxide/
H2O2 at measurable rates [21]. In this study we characterized the
production of superoxide/H2O2 from dihydroorotate dehydrogen-
ase, the only redox step of the de novo pyrimidine biosynthesis
pathway, in mitochondria isolated from rat skeletal muscle. The
ability of dihydroorotate dehydrogenase to produce superoxide/
H2O2 was previously ambiguous [7–9]. Our results show that
dihydroorotate oxidation caused a signiﬁcant reduction of the
Q-pool (when reoxidation of the Q-pool was prevented by inhibit-
ing complex III with antimycin A and myxothiazol). This degree of
reduction was fully capable of driving considerable H2O2 produc-
tion from sites that accept electrons from this pool. Approximately
80% of the observed rate of production of H2O2 in the presence of
dihydroorotate was sensitive to malonate and atpenin A5, showing
that this proportion of the total was from site IIF. When all known
sites were inhibited (speciﬁcally, sites IQ, IF, IIF, and IIIQo) there was
still a signiﬁcant rate of superoxide/H2O2 production of 237
2 pmol min1 mg protein1. This lower rate was sensitive to
brequinar (Fig. 6), showing that it was dependent on oxidation
of dihydroorotate. Together, these observations strongly suggest
Fig. 5. Effects of brequinar and leﬂunomide on respiration driven by various substrates. The effects of 10 μM brequinar or 20 μM leﬂunomide on the uncoupled oxygen
consumption of rat skeletal muscle mitochondria induced by (a) 5 mM succinate plus 4 μM rotenone, (b) 5 mM glutamate plus 5 mM malate, (c) 5 mM glycerol 3-phosphate
plus 4 μM rotenone, and (d) 15 μM palmitoyl-L-carnitine plus 2 mM carnitine are shown. Mitochondria were assayed in a 24-well Seahorse plate containing KHEPMB
medium in the presence of 1 μM FCCP, 1 mM ADP, and 1 μg ml1 oligomycin. Data are means7SEM (n ¼ 3). np o 0.05 compared to control (DMSO vehicle only).
Fig. 6. Superoxide/H2O2 production speciﬁcally from dihydroorotate dehydrogen-
ase. Rat skeletal muscle mitochondria were incubated in the presence of 4 μM
rotenone, 2 μM antimycin A, 2 μM myxothiazol, 5 mM malonate, 1 μM atpenin A5,
and 3.5 mM dihydroorotate. In parallel 10 μM brequinar or 20 μM leﬂunomide was
also added where indicated. The brequinar-sensitive rate attributed to dihydroor-
otate dehydrogenase was 23.272.3 pmol H2O2 min1 mg protein1. Data are
means7SEM (n ¼ 4). np o 0.05 compared to control (DMSO vehicle only).
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that it arose from dihydroorotate dehydrogenase itself. Brequinar
binds to the ubiquinone binding site in dihydroorotate dehydro-
genase [26], leaving the ﬂavin site open for reduction when
dihydroorotate is present. Because brequinar inhibits superoxide/
H2O2 production by dihydroorotate dehydrogenase (Fig. 6), our
results show that the ubiquinone handling part of the enzyme
produces superoxide/H2O2, and not the ﬂavin site as previously
thought [2]. Compared to the rates from other known mitochon-
drial sites, the maximum rate from dihydroorotate dehydrogenase
is the lowest determined so far: 10% of the maximum rate from the
ETF/ETF:QOR system of fatty acid oxidation and 0.5% of the
maximum rate from site IIIQo [21]. However, dihydroorotate
oxidation is able to sustain much higher rates of superoxide/
H2O2 production indirectly from other sites, so even if dihydroor-
otate dehydrogenase is not the primary source of superoxide/
H2O2, dihydroorotate oxidation may still be able to generate
enough superoxide/H2O2 to have cellular effects, and brequinar
and leﬂunomide may be able to prevent such effects.
In this study we used 3.5 mM dihydroorotate to induce max-
imal superoxide/H2O2 production. Half-maximal production was
reached at 10 mM dihydroorotate (Fig. 3a). Previous studies
found Km values for dihydroorotate in the same range (6.1 mM)
in rat liver mitochondria [22]. The intracellular concentration of
dihydroorotate is also in the low micromolar range (1–12 mM)
[28,29]. The dihydroorotate concentration we used routinely is
probably above the physiological range but it would have been
difﬁcult to detect the superoxide/H2O2 production from dihydroor-
otate dehydrogenase itself at lower dihydroorotate concentrations.
Nevertheless, low micromolar concentrations of dihydroorotate
can cause signiﬁcant mitochondrial superoxide/H2O2 production
(e.g., 54 pmol H2O2 min1 mg protein1 at 5 mM dihydroorotate,
Fig. 3a). Thus, dihydroorotate oxidation may be capable of con-
tributing to mitochondrial superoxide/H2O2 production in vivo.
Production of reactive oxygen species by dihydroorotate dehy-
drogenase itself has been implicated in apoptosis in cancer cells
[10,30]. Brequinar and leﬂunomide inhibit dihydroorotate dehy-
drogenase activity and decrease the content of uridine in cells [10]
and cause cell cycle arrest and apoptosis [10,30,31]. However, it
remains unclear whether superoxide/H2O2 from dihydroorotate
dehydrogenase itself or from other sites contributes to apoptosis in
these cells; the low capacity of the enzyme itself suggests that if
reactive oxygen species are involved, they arise from other
mitochondrial sites driven by electrons from dihydroorotate, and
not from dihydroorotate dehydrogenase itself.
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